Intuitive Surgical Opens New UK/Ireland HQ In Oxfordshire
• By Catherine Longworth
Generate a summary of this article
Listen to this article
Surgical robotics giant Intuitive Surgical has opened a new UK and Ireland headquarters and training suite in Oxford. The California company expects the new facility to help expand business across the region.
Attendees at the opening of Intuitive Surgical's new UK HQ in Oxford Science Park • Source: Intuitive Surgical
Intuitive Surgical Inc. has landed its first UK headquarters and training suite in Oxford in a bid to penetrate the UK and Ireland markets further.
The Sunnyvale, California-based company first introduced da Vinci robotic surgical systems in the UK in 2000 and has placed more...
Keep up with the top medtech business and regulatory news.
Medtech Insight brings you interviews and analysis, on the go.
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 40 documents have been posted on the tracker since its last update.
UK-based Biocomposites will begin selling in the UK its next-generation osteoinductive bone graft substitute, NanoBone, which came with its acquisition of Artoss GmbH in June 2023. Meanwhile, the company has purchased remaining shares in the manufacturers of SYNICEM and Subiton antibiotic bone cements and preformed antibiotic-loaded spacers.
The firm’s dual-chamber leadless pacemaker system with is expected to be a growth driver for Abbott and already has acquired approximately 30%-40% of market share from Medtronic since its approval by the US FDA in July 2023, according to GlobalData.
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Nearly 80 documents have been posted on the tracker since its last update.
UK-based Biocomposites will begin selling in the UK its next-generation osteoinductive bone graft substitute, NanoBone, which came with its acquisition of Artoss GmbH in June 2023. Meanwhile, the company has purchased remaining shares in the manufacturers of SYNICEM and Subiton antibiotic bone cements and preformed antibiotic-loaded spacers.
The firm’s dual-chamber leadless pacemaker system with is expected to be a growth driver for Abbott and already has acquired approximately 30%-40% of market share from Medtronic since its approval by the US FDA in July 2023, according to GlobalData.
Amferia is developing an antimicrobial peptide hydrogel dressing to combat infections in acute wounds in humans and veterinary contexts. Supported by €1.2m of new venture capital financing, the company is planning pivotal clinical studies to support an FDA application later this year and CE mark submission in 2026-2027.